Bioresorbable polystatin fourth-generation stents.

Area of Science:

• Biomaterials Science
• Polymer Chemistry
• Cardiovascular Engineering

Background:

• Current bioresorbable stents (BRS) are third-generation devices, featuring drug-eluting polymers but pharmacologically inactive scaffolds.
• Existing scaffolds present an opportunity for delivering additional therapeutic agents to target specific vascular complications.
• Impaired re-endothelialization and stent thrombosis remain significant challenges in cardiovascular interventions.

Purpose of the Study:

• To explore the modification of a bioresorbable polymer to serve as a dual-function stent scaffold.
• To investigate the covalent incorporation of lovastatin into a terpolymer backbone.
• To assess the feasibility of creating a fourth-generation BRS capable of delivering two drugs.

Main Methods:

• A standard bioresorbable terpolymer composed of lactide, glycolide, and ε-caprolactone was modified.
• Lovastatin was covalently incorporated into the polymer backbone via a reaction at 100°C for 18 hours.
• The resulting terpolymer was fabricated into a stent scaffold using a novel rapid prototyping technique (RSF system).

Main Results:

• Successful covalent incorporation of lovastatin into the terpolymer backbone was confirmed using Nuclear Magnetic Resonance (NMR) spectroscopy.
• The terpolymer composition was determined to be lactide, glycolide, ε-caprolactone, and lovastatin in a 60:15:10:15 weight ratio.
• A novel stent scaffold was successfully fabricated from the modified terpolymer.

Conclusions:

• It is preliminarily feasible to create a fourth-generation bioresorbable stent.
• This novel stent scaffold has the potential to deliver two therapeutic agents.
• This approach could enhance treatment outcomes for vessel lumen injury, restenosis, and stent thrombosis.